144 related articles for article (PubMed ID: 12491803)
1. [COX inhibitor, suppression of polyposis, and chemoprevention].
Oshima M; Taketo MM
Nihon Yakurigaku Zasshi; 2002 Nov; 120(5):276-84. PubMed ID: 12491803
[TBL] [Abstract][Full Text] [Related]
2. COX selectivity and animal models for colon cancer.
Oshima M; Taketo MM
Curr Pharm Des; 2002; 8(12):1021-34. PubMed ID: 11945149
[TBL] [Abstract][Full Text] [Related]
3. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
Oshima M; Dinchuk JE; Kargman SL; Oshima H; Hancock B; Kwong E; Trzaskos JM; Evans JF; Taketo MM
Cell; 1996 Nov; 87(5):803-9. PubMed ID: 8945508
[TBL] [Abstract][Full Text] [Related]
4. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
[TBL] [Abstract][Full Text] [Related]
6. Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality.
Rüegg C; Zaric J; Stupp R
Ann Med; 2003; 35(7):476-87. PubMed ID: 14649330
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks.
Moran EM
J Environ Pathol Toxicol Oncol; 2002; 21(2):193-201. PubMed ID: 12086406
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.
Khan KN; Masferrer JL; Woerner BM; Soslow R; Koki AT
Scand J Gastroenterol; 2001 Aug; 36(8):865-9. PubMed ID: 11495083
[TBL] [Abstract][Full Text] [Related]
9. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
10. Use of NSAIDs for the chemoprevention of colorectal cancer.
Herendeen JM; Lindley C
Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
[TBL] [Abstract][Full Text] [Related]
11. Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522.
Sasai H; Masaki M; Wakitani K
Carcinogenesis; 2000 May; 21(5):953-8. PubMed ID: 10783317
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate.
Rao CV; Cooma I; Rodriguez JG; Simi B; El-Bayoumy K; Reddy BS
Carcinogenesis; 2000 Apr; 21(4):617-21. PubMed ID: 10753194
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
Kitamura T; Itoh M; Noda T; Matsuura M; Wakabayashi K
Int J Cancer; 2004 Apr; 109(4):576-80. PubMed ID: 14991580
[TBL] [Abstract][Full Text] [Related]
14. Piroxicam-induced regression of intestinal adenomatous polyps in APC(delta474) mice.
Qiu ZF; Maruyama K; Sunayama K; Kashiwabara H; Shoji T; Nakamura T; Suzuki S; Konno H; Nakamura S
J Invest Surg; 2003; 16(2):71-81. PubMed ID: 12746190
[TBL] [Abstract][Full Text] [Related]
15. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps.
Sonoshita M; Takaku K; Oshima M; Sugihara K; Taketo MM
Cancer Res; 2002 Dec; 62(23):6846-9. PubMed ID: 12460897
[TBL] [Abstract][Full Text] [Related]
17. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice.
Sonoshita M; Takaku K; Sasaki N; Sugimoto Y; Ushikubi F; Narumiya S; Oshima M; Taketo MM
Nat Med; 2001 Sep; 7(9):1048-51. PubMed ID: 11533709
[TBL] [Abstract][Full Text] [Related]
18. [Effects of nonsteroidal anti-inflammatory drugs (NSAID) on colorectal polyps in patients with familial adenomatous polyposis: a review of clinical studies].
Akasu T; Kakizoe T
Nihon Geka Gakkai Zasshi; 1998 Jun; 99(6):385-90. PubMed ID: 9695077
[TBL] [Abstract][Full Text] [Related]
19. COX-2 and colon cancer.
Taketo MM
Inflamm Res; 1998 Oct; 47 Suppl 2():S112-6. PubMed ID: 9831333
[TBL] [Abstract][Full Text] [Related]
20. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.
Takeda H; Sonoshita M; Oshima H; Sugihara K; Chulada PC; Langenbach R; Oshima M; Taketo MM
Cancer Res; 2003 Aug; 63(16):4872-7. PubMed ID: 12941808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
